Roche reports strong sales growth in the first quarter of 2015
- Details
- Category: Roche
The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in Pharmaceuticals, and immunodiagnostics products driving growth in Diagnostics.
United States first country to launch Saxenda®
- Details
- Category: Novo Nordisk
Novo Nordisk today announced that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada.
GSK to establish global vaccines R&D centre in the US
- Details
- Category: GlaxoSmithKline
GSK is further strengthening and expanding its vaccines presence in the US by establishing a new global centre for vaccines research and development (R&D) in Rockville, Maryland. The site will become one of three global vaccines R&D centres for GSK, complementing the company's existing global R&D centres in Rixensart, Belgium and in Siena, Italy, a site which GSK recently acquired from Novartis in March 2015.
New international survey of lung cancer oncologists highlights underutilization of personalized treatments
- Details
- Category: Boehringer Ingelheim
Results from a new global survey of lung cancer oncologists have shown that despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for EGFR mutations, a significant number of those tested were not receiving personalized treatments for their cancer type and mutation subtype.
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America
- Details
- Category: Bristol-Myers Squibb
Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux® (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers Squibb to Lilly.
AstraZeneca and PatientsLikeMe announce global research collaboration
- Details
- Category: AstraZeneca
In a major step forward to make patient-centric evidence a cornerstone of scientific discovery and development, AstraZeneca and PatientsLikeMe have signed a five-year agreement to provide access to PatientsLikeMe’s global network in support of AstraZeneca's patient-driven research initiatives.
Novo Nordisk opens new insulin formulation and filling facility in Russia
- Details
- Category: Novo Nordisk
Today, Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market.
More Pharma News ...
- UCB to focus on core business in India
- Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
- AstraZeneca joins Genomics England consortium
- GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US
- AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
- Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases
- Pfizer and Lilly preparing to resume Phase 3 chronic pain program for Tanezumab